{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:05:54Z","timestamp":1794805554160,"version":"4.9.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T00:00:00Z","timestamp":1678665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Future Fund, Australia","award":["MRF1199701"],"award-info":[{"award-number":["MRF1199701"]}],"id":[{"id":"https:\/\/ror.org\/0513v5k17","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Medical Research Future Fund, Australia","award":["MRF1200535"],"award-info":[{"award-number":["MRF1200535"]}],"id":[{"id":"https:\/\/ror.org\/0513v5k17","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>NTRK<\/jats:italic>\n                    gene fusions are rare somatic mutations found across cancer types with promising targeted therapies emerging. Healthcare systems face significant challenges in integrating these treatments, with uncertainty in prevalence and optimal testing methods to identify eligible patients. We performed a systematic review of\n                    <jats:italic>NTRK<\/jats:italic>\n                    fusion prevalence to inform efficient diagnostic screening and scale of therapeutic uptake. We searched Medline, Embase and Cochrane databases on 31\/03\/2021. Inclusion criteria were studies reporting fusion rates in solid tumours, English language, post-2010 publication and minimum sample size. Critical appraisal was performed using a custom 11-item checklist\n                    <jats:italic>.<\/jats:italic>\n                    Rates were collated by cancer type and pooled if additional synthesis criteria were met. 160 studies were included, with estimates for 15 pan-cancer and 429 specific cancer types (63 paediatric). Adult pan-cancer estimates ranged 0.03\u20130.70%, with higher rates found in RNA-based assays\n                    <jats:italic>.<\/jats:italic>\n                    In common cancers, rates were consistently below 0.5%. Rare morphological subtypes, colorectal microsatellite instability, and driver mutation exclusion cancers had higher rates. Only 35.6% of extracted estimates used appropriate methods and sample size to identify\n                    <jats:italic>NTRK<\/jats:italic>\n                    fusions.\n                    <jats:italic>NTRK<\/jats:italic>\n                    fusion-positive cancers are rare and widely distributed across solid tumours. Small-scale, heterogeneous data confound prevalence prediction. Further large-scale, standardised genomic data are needed to characterise\n                    <jats:italic>NTRK<\/jats:italic>\n                    fusion epidemiology.\n                  <\/jats:p>","DOI":"10.1038\/s41598-023-31055-3","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T08:41:20Z","timestamp":1678696880000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Systematic review of NTRK 1\/2\/3 fusion prevalence pan-cancer and across solid tumours"],"prefix":"10.1038","volume":"13","author":[{"given":"Sophie","family":"O\u2019Haire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Jung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Canfell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"IJzerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,13]]},"reference":[{"issue":"7","key":"31055_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.annonc.2020.03.299","volume":"31","author":"T Yoshino","year":"2020","unstructured":"Yoshino, T. et al. JSCO-ESMO-ASCO-JSMO-TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann. Oncol. 31(7), 861\u2013872 (2020).","journal-title":"Ann. Oncol."},{"key":"31055_CR2","doi-asserted-by":"crossref","unstructured":"Drilon, A. et al. A phase II basket study of the oral TRK inhibitor LOXO-101 in adult subjects with NTRK fusion-positive tumors. Annals of Oncology. Conference: 41st European society for medical oncology congress, ESMO 2016. Conference start: 20161007. Conference end: 20161011. 27 (2016).","DOI":"10.1093\/annonc\/mdw368.52"},{"issue":"Suppl 8","key":"31055_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy424.017","volume":"29","author":"GD Demetri","year":"2018","unstructured":"Demetri, G. D. et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372\u2013001. Ann. Oncol. 29(Suppl 8), viii713 (2018).","journal-title":"Ann. Oncol."},{"key":"31055_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6435","volume":"368","author":"S Cooper","year":"2020","unstructured":"Cooper, S. et al. How should we assess the clinical and cost effectiveness of histology independent cancer drugs?. BMJ 368, l6435 (2020).","journal-title":"BMJ"},{"issue":"7","key":"31055_CR5","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1158\/1078-0432.CCR-19-3165","volume":"26","author":"EY Rosen","year":"2020","unstructured":"Rosen, E. Y. et al. Trk fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin. Cancer Res. 26(7), 1624\u20131632 (2020).","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"31055_CR6","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","volume":"21","author":"SJ Hsiao","year":"2019","unstructured":"Hsiao, S. J. et al. Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy. J. Mol. Diagn. 21(4), 553\u2013571 (2019).","journal-title":"J. Mol. Diagn."},{"issue":"1","key":"31055_CR7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","volume":"33","author":"JP Solomon","year":"2020","unstructured":"Solomon, J. P. et al. NTRK fusion detection across multiple assays and 33,997 cases: Diagnostic implications and pitfalls. Mod. Pathol. 33(1), 38\u201346 (2020).","journal-title":"Mod. Pathol."},{"issue":"13","key":"31055_CR8","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","volume":"79","author":"JP Solomon","year":"2019","unstructured":"Solomon, J. P. & Hechtman, J. F. Detection of NTRK fusions: Merits and limitations of current diagnostic platforms. Cancer Res. 79(13), 3163\u20133168 (2019).","journal-title":"Cancer Res."},{"issue":"12","key":"31055_CR9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","volume":"15","author":"E Cocco","year":"2018","unstructured":"Cocco, E., Scaltriti, M. & Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15(12), 731\u2013747 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"31055_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41379-021-00913-8","volume":"35","author":"JF Hechtman","year":"2022","unstructured":"Hechtman, J. F. NTRK insights: Best practices for pathologists. Mod. Pathol. 35, 298\u2013305 (2022).","journal-title":"Mod. Pathol."},{"issue":"Suppl 8","key":"31055_CR11","doi-asserted-by":"publisher","first-page":"VIII16","DOI":"10.1093\/annonc\/mdz384","volume":"30","author":"JP Solomon","year":"2019","unstructured":"Solomon, J. P. et al. Identifying patients with NTRK fusion cancer. Ann. Oncol. 30(Suppl 8), VIII16\u2013VIII22 (2019).","journal-title":"Ann. Oncol."},{"issue":"10","key":"31055_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103718","volume":"21","author":"FZ Marino","year":"2020","unstructured":"Marino, F. Z. et al. Ntrk fusions, from the diagnostic algorithm to innovative treatment in the era of precision medicine. Int. J. Mol. Sci. 21(10), 3718 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"31055_CR13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10147-019-01610-y","volume":"25","author":"Y Naito","year":"2020","unstructured":"Naito, Y. et al. Japan society of clinical oncology\/Japanese society of medical oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-positive advanced solid tumors, cooperated by the Japanese society of pediatric hematology\/oncology. Int. J. Clin. Oncol. 25(3), 403\u2013417 (2020).","journal-title":"Int. J. Clin. Oncol."},{"issue":"11","key":"31055_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.annonc.2020.08.2232","volume":"31","author":"GD Demetri","year":"2020","unstructured":"Demetri, G. D. et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: Expert recommendations from the World Sarcoma Network. Ann. Oncol. 31(11), 1506\u20131517 (2020).","journal-title":"Ann. Oncol."},{"issue":"1","key":"31055_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","volume":"5","author":"CB Westphalen","year":"2021","unstructured":"Westphalen, C. B. et al. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis. Oncol. 5(1), 69 (2021).","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"31055_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.trecan.2020.08.009","volume":"7","author":"JJ Adashek","year":"2021","unstructured":"Adashek, J. J., Subbiah, V. & Kurzrock, R. From tissue-agnostic to N-of-one therapies: (R)evolution of the precision paradigm. Trends Cancer 7(1), 15\u201328 (2021).","journal-title":"Trends Cancer"},{"key":"31055_CR17","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40265-020-01459-w","volume":"81","author":"KS Rohrberg","year":"2021","unstructured":"Rohrberg, K. S. & Lassen, U. Detecting and targeting NTRK fusions in cancer in the era of tumor agnostic oncology. Drugs 81, 445\u2013452 (2021).","journal-title":"Drugs"},{"key":"31055_CR18","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920975613","author":"A Forsythe","year":"2020","unstructured":"Forsythe, A. et al. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Ther. Adv. Med. Oncol. https:\/\/doi.org\/10.1177\/1758835920975613 (2020).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"31055_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"key":"31055_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jclinepi.2020.06.039","volume":"127","author":"CB Migliavaca","year":"2020","unstructured":"Migliavaca, C. B. et al. Quality assessment of prevalence studies: A systematic review. J. Clin. Epidemiol. 127, 59\u201368 (2020).","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"31055_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","volume":"13","author":"Z Munn","year":"2015","unstructured":"Munn, Z. et al. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int. J. Evid. Based Healthc. 13(3), 147\u2013153 (2015).","journal-title":"Int. J. Evid. Based Healthc."},{"issue":"9","key":"31055_CR22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","volume":"65","author":"D Hoy","year":"2012","unstructured":"Hoy, D. et al. Assessing risk of bias in prevalence studies: Modification of an existing tool and evidence of interrater agreement. J. Clin. Epidemiol. 65(9), 934\u2013939 (2012).","journal-title":"J. Clin. Epidemiol."},{"key":"31055_CR23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-0716-1566-9_10","volume":"2345","author":"G Schwarzer","year":"2022","unstructured":"Schwarzer, G. & R\u00fccker, G. Meta-analysis of proportions. Methods Mol. Biol. 2345, 159\u2013172 (2022).","journal-title":"Methods Mol. Biol."},{"issue":"7","key":"31055_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41379-019-0212-1","volume":"32","author":"J Wang","year":"2019","unstructured":"Wang, J. et al. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Mod. Pathol. 32(7), 1053\u20131064 (2019).","journal-title":"Mod. Pathol."},{"issue":"8","key":"31055_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1007\/s12094-018-02030-6","volume":"21","author":"CB Westphalen","year":"2019","unstructured":"Westphalen, C. B. et al. Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: Pooled data from three independent cohorts. Clin. Transl. Oncol. 21(8), 1108\u20131111 (2019).","journal-title":"Clin. Transl. Oncol."},{"issue":"19","key":"31055_CR26","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-19-0899","volume":"25","author":"CH Lieu","year":"2019","unstructured":"Lieu, C. H. et al. Comprehensive genomic landscapes in early and later onset colorectal cancer. Clin. Cancer Res. 25(19), 5852\u20135858 (2019).","journal-title":"Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31055-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31055-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31055-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T08:42:52Z","timestamp":1678696972000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31055-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31055"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31055-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,13]]},"assertion":[{"value":"28 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4116"}}